Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 5/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.38 |
| ▸ | NPY4R | P50391 | 5/20 | 0.38 |
| ▸ | NPY1R | P25929 | 4/20 | 0.38 |
| ▸ | NPY2R | P49146 | 2/20 | 0.38 |
| ▸ | FURIN | P09958 | 2/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.35 |
| ▸ | NMT2 | O60551 | 1/20 | 0.35 |
| ▸ | NMT1 | P30419 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.34 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3244447 | 1.00 | FAP (0.44) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL15246622 | 1.00 | FAP (0.44) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL21416485 | 1.00 | FAP (0.44) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL24848129 | 0.99 | FAP (0.44) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL23286101 | 0.97 | FAP (0.42) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL18244334 | 0.94 | FAP (0.40) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL18244335 | 0.94 | FAP (0.40) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL22952275 | 0.94 | FAP (0.44) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL24520454 | 0.94 | FAP (0.47) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL20808481 | 0.94 | FAP (0.44) | FAPNPY5RNPY4RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497460-B2 | Anti-MSR1 antibodies and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| EP-4653017-A1 | ANTIBODY-DRUG CONJUGATE AND USE THEREOF | Tyligand Bioscience (Shanghai) Limited (CN) | 2025-11-26 | — | — | EP | disclosed |
| US-20250064954-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2025-02-27 | — | — | US | disclosed |
| CN-118873678-A | Antibody-conjugated drugs and uses thereof | 泰励生物科技（上海）有限公司 | 2024-11-01 | — | — | CN | disclosed |
| US-20240342299-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | REGENERON PHARMA (US) | 2024-10-17 | — | — | US | disclosed |
| US-12070506-B2 | Steroids and antibody-conjugates thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2024-08-27 | — | — | US | disclosed |
| US-20240252671-A1 | NEODEGRADER-ANTI-CD33 ANTIBODY CONJUGATES | ORUM THERAPEUTICS INC (KR) | 2024-08-01 | — | — | US | disclosed |
| WO-2024153127-A1 | ANTIBODY-DRUG CONJUGATE AND USE THEREOF | 泰励生物科技（上海）有限公司 | 2024-07-25 | — | — | WO | disclosed |
| EP-4346910-A1 | NEODEGRADER-ANTI-CD33 ANTIBODY CONJUGATES | Orum Therapeutics Inc. (KR) | 2024-04-10 | — | — | EP | disclosed |
| WO-2024067841-A1 | BENZAZEPINE DERIVATIVE, CONJUGATE CONTAINING SAME, AND USE THEREOF | 上海迪诺医药科技有限公司 | 2024-04-04 | — | — | WO | disclosed |
| US-20170095570-A1 | PYRROLOBENZODIAZEPINE ANTIBODY DRUG CONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2017-04-06 | — | — | US | disclosed |
| US-20160354485-A1 | 1-(CHLOROMETHYL)-2,3-DIHYDRO-1H-BENZO[E]INDOLE DIMER ANTIBODY-DRUG CONJUGATE COMPOUNDS, AND METHODS OF USE AND TREATMENT | GENENTECH, INC. (US) | 2016-12-08 | — | — | US | disclosed |
| WO-2016046574-A1 | BIOLOGICAL MATERIALS AND USES THEREOF | ANTIKOR BIOPHARMA LIMITED (GB) | 2016-03-31 | — | — | WO | disclosed |
| US-20160074529-A1 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES | GENENTECH, INC. (US) | 2016-03-17 | — | — | US | disclosed |
| US-20150366990-A1 | ANTIBODY-LINKER-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND ANTICANCER DRUG COMPOSITION CONTAINING SAME | CELLTRION, INC. (KR) | 2015-12-24 | — | — | US | disclosed |
| US-20150366985-A1 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES | GENENTECH, INC. (US) | 2015-12-24 | — | — | US | disclosed |
| EP-2927227-A1 | ANTIBODY-LINKER-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND ANTICANCER DRUG COMPOSITION CONTAINING SAME | Celltrion, Inc. (KR) | 2015-10-07 | — | — | EP | disclosed |
| US-20150165063-A1 | 1-(CHLOROMETHYL)-2,3-DIHYDRO-1H-BENZO[E]INDOLE DIMER ANTIBODY-DRUG CONJUGATE COMPOUNDS, AND METHODS OF USE AND TREATMENT | AUCKLAND CANCER SOCIETY RESEARCH CENTRE (NZ) | 2015-06-18 | — | — | US | disclosed |
| US-20140356376-A1 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES | GENENTECH, INC. (US) | 2014-12-04 | — | — | US | disclosed |
| US-20140356375-A1 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES | GENENTECH, INC. (US) | 2014-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240342299-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | SERPINA6, NR3C1, NR3C2 | FAP 2921/4885NPY5R 2634/4885NPY4R 2560/4885 |
| US-12070506-B2 | Steroids and antibody-conjugates thereof | SERPINA6, NR3C1, NR3C2 | FAP 2921/4885NPY5R 2634/4885NPY4R 2560/4885 |
| US-20150165063-A1 | 1-(CHLOROMETHYL)-2,3-DIHYDRO-1H-BENZO[E]INDOLE DIMER ANTIBODY-DRUG CONJUGATE COMPOUNDS, AND METHODS OF USE AND TREATMENT | IDO1, DBI, IDO2 | FAP 3227/4885NPY5R 420/4885NPY4R 394/4885 |
| US-20150366985-A1 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES | STT3A, STT3B, DDOST | FAP 4221/4885NPY5R 3485/4885NPY4R 4262/4885 |
| US-20240252671-A1 | NEODEGRADER-ANTI-CD33 ANTIBODY CONJUGATES | NEU3, FCGR3B, ENTPD3 | FAP 272/4885NPY5R 1923/4885NPY4R 1822/4885 |
| US-20140356375-A1 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES | STT3A, STT3B, DDOST | FAP 4221/4885NPY5R 3485/4885NPY4R 4262/4885 |
| US-20250064954-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | SERPINA6, NR3C1, NR3C2 | FAP 2921/4885NPY5R 2634/4885NPY4R 2560/4885 |
| US-20140356376-A1 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES | STT3A, STT3B, DDOST | FAP 4221/4885NPY5R 3485/4885NPY4R 4262/4885 |
| US-20160354485-A1 | 1-(CHLOROMETHYL)-2,3-DIHYDRO-1H-BENZO[E]INDOLE DIMER ANTIBODY-DRUG CONJUGATE COMPOUNDS, AND METHODS OF USE AND TREATMENT | IDO1, DBI, IDO2 | FAP 3227/4885NPY5R 420/4885NPY4R 394/4885 |
| US-12497460-B2 | Anti-MSR1 antibodies and methods of use thereof | CD47, MSR1, LDLR | FAP 4480/4885NPY5R 1833/4885NPY4R 2033/4885 |
| US-20160074529-A1 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES | STT3A, STT3B, DDOST | FAP 4221/4885NPY5R 3485/4885NPY4R 4262/4885 |
| US-20150366990-A1 | ANTIBODY-LINKER-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND ANTICANCER DRUG COMPOSITION CONTAINING SAME | WEE1, NOTUM, WEE2 | FAP 1818/4885NPY5R 3797/4885NPY4R 3670/4885 |
| US-20170095570-A1 | PYRROLOBENZODIAZEPINE ANTIBODY DRUG CONJUGATES AND METHODS OF USE | GABRA5, BCR, GABRA4 | FAP 4322/4885NPY5R 402/4885NPY4R 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.